T1	CHEM 15 25	rapamicina
#1	AnnotatorNotes T1	C0072980; sirolimus; Organic Chemical · Antibiotic
T2	DISO 33 48	angiomiolipomas
#2	AnnotatorNotes T2	C0206633; Angiomyolipoma; Neoplastic Process
T3	DISO 66 85	esclerosis tuberosa
#3	AnnotatorNotes T3	C0041341; Tuberous Sclerosis; Neoplastic Process
T4	CHEM 453 482	mammalian target of rapamycin
T5	DISO 104 123	esclerosis tuberosa
#4	AnnotatorNotes T5	C0041341; Tuberous Sclerosis; Neoplastic Process
T6	DISO 136 156	enfermedad sistémica
#5	AnnotatorNotes T6	C0442893; Systemic disease; Disease or Syndrome
T7	DISO 273 280	tumores
#6	AnnotatorNotes T7	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T8	DISO 282 294	angiolipomas
#7	AnnotatorNotes T8	C0206632; Angiolipoma; Neoplastic Process
T9	DISO 302 315	angiofibromas
#8	AnnotatorNotes T9	C0206731; Angiofibroma; Neoplastic Process
T10	DISO 317 329	astrocitomas
#9	AnnotatorNotes T10	C0004114; Astrocytoma; Neoplastic Process
T11	DISO 395 397	ET
#10	AnnotatorNotes T11	C0041341; Tuberous Sclerosis; Neoplastic Process
T12	DISO 587 590	AML
#11	AnnotatorNotes T12	C0206632; Angiolipoma; Neoplastic Process
T13	DISO 794 797	AML
#12	AnnotatorNotes T13	C0206632; Angiolipoma; Neoplastic Process
T14	CHEM 422 451	inhibidores de la kinasa mTOR
#13	AnnotatorNotes T14	C2746052; MTOR Inhibitors; Pharmacologic Substance
T15	CHEM 493 503	rapamicina
#14	AnnotatorNotes T15	C0072980; sirolimus; Organic Chemical · Antibiotic
T16	DISO 568 570	ET
#15	AnnotatorNotes T16	C0041341; Tuberous Sclerosis; Neoplastic Process
T17	PROC 617 630	diagnosticado
#16	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	PROC 635 655	resonancia magnética
#17	AnnotatorNotes T18	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T19	PROC 657 659	RM
#18	AnnotatorNotes T19	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T20	PROC 675 686	tratamiento
#19	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	PROC 804 816	monitorizado
#20	AnnotatorNotes T21	C1283169; Monitoring; Health Care Activity
T22	PROC 841 853	RM abdominal
#21	AnnotatorNotes T22	C3842374; MRI scan - abdominal; Diagnostic Procedure
T23	ANAT 844 853	abdominal
#22	AnnotatorNotes T23	C0000726; Abdomen; Body Location or Region | C1281594; Entire abdomen; Body Part, Organ, or Organ Component
T24	PROC 1589 1597	tratados
#23	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 907 909	RM
#24	AnnotatorNotes T25	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T26	ANAT 732 743	plasmáticos
#25	AnnotatorNotes T26	C0032105; Plasma; Body Substance
T27	DISO 1209 1228	efectos secundarios
#26	AnnotatorNotes T27	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T28	DISO 1250 1262	aftas orales
#27	AnnotatorNotes T28	C0038363; Aphthous Stomatitis; Disease or Syndrome
T29	DISO 1271 1291	hipertrigliceridemia
#28	AnnotatorNotes T29	C0020557; Hypertriglyceridemia; Disease or Syndrome
T30	DISO 1300 1312	microcitosis
#29	AnnotatorNotes T30	C0221265; Microcytosis; Finding
T31	DISO 1315 1325	hipocromía
#30	AnnotatorNotes T31	C0333912; Hypochromatism; Finding
T32	DISO 1334 1341	diarrea
#31	AnnotatorNotes T32	C0011991; Diarrhea; Sign or Symptom
T33	DISO 1350 1354	acné
#32	AnnotatorNotes T33	C0702166; Acne; Disease or Syndrome
T34	DISO 1363 1382	pielonefritis aguda
#33	AnnotatorNotes T34	C0520575; Acute pyelonephritis; Disease or Syndrome
T35	DISO 1393 1404	proteinuria
#34	AnnotatorNotes T35	C0033687; Proteinuria; Finding
T36	CHEM 1476 1486	rapamicina
#35	AnnotatorNotes T36	C0072980; sirolimus; Organic Chemical · Antibiotic
T37	PROC 1531 1542	tratamiento
#36	AnnotatorNotes T37	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T38	DISO 1665 1668	AML
#37	AnnotatorNotes T38	C0206632; Angiolipoma; Neoplastic Process
T39	ANAT 170 180	autosómica
#38	AnnotatorNotes T39	C0596142; Autosome; Cell Component
T40	CHEM 691 701	rapamicina
#39	AnnotatorNotes T40	C0072980; sirolimus; Organic Chemical · Antibiotic
T41	DISO 958 961	AML
#40	AnnotatorNotes T41	C0206632; Angiolipoma; Neoplastic Process
T42	ANAT 1256 1262	orales
#41	AnnotatorNotes T42	C0226896; Oral cavity; Body Space or Junction | C0230028; Oral region; Body Location or Region | C1267547; Entire mouth region; Body Space or Junction
T43	DISO 1549 1551	ET
#42	AnnotatorNotes T43	C0041341; Tuberous Sclerosis; Neoplastic Process
T44	DISO 125 127	ET
#43	AnnotatorNotes T44	C0041341; Tuberous Sclerosis; Neoplastic Process
T45	DISO 207 217	mutaciones
#44	AnnotatorNotes T45	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T46	DISO 296 299	AML
#45	AnnotatorNotes T46	C0206632; Angiolipoma; Neoplastic Process
T47	LIVB 52 61	pacientes
#46	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	PHYS 161 190	herencia autosómica dominante
#47	AnnotatorNotes T48	C0443147; Autosomal dominant inheritance; Genetic Function
T49	GENE 225 230	genes
#48	AnnotatorNotes T49	C0017337; Genes; Gene or Genome
T51	LIVB 545 554	pacientes
#49	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	Duration 710 718	12 meses
T53	Frequency 817 831	semestralmente
T54	Duration 870 882	los 12 meses
T55	LIVB 975 984	pacientes
#50	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T59	LIVB 1579 1588	pacientes
#51	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	Duration 1606 1614	12 meses
T61	GENE 232 236	TSC1
#52	AnnotatorNotes T61	C0694894; TSC1 gene; Gene or Genome
T62	GENE 239 243	TSC2
#53	AnnotatorNotes T62	C0694895; TSC2 gene; Gene or Genome
T50	Spec_cue 1487 1492	puede
T56	CONC 1507 1512	papel
A1	Assertion T56 Speculated
#54	AnnotatorNotes T56	C1280500; Effect; Qualitative Concept
T57	Quantifier_or_Qualifier 1513 1524	beneficioso
A2	Assertion T57 Speculated
R1	Has_Quantifier_or_Qualifier Arg1:T56 Arg2:T57	
R2	Speculation Arg1:T50 Arg2:T56	
R3	Speculation Arg1:T50 Arg2:T57	
#55	AnnotatorNotes T4	C1307407; FRAP1 protein, human;  Amino Acid, Peptide, or Protein · Enzyme 
T58	Observation 1 8	Efectos
#56	AnnotatorNotes T58	C1518681; Outcome of Therapy; Finding (?)
R4	Causes Arg1:T1 Arg2:T58	
R5	Experiences Arg1:T47 Arg2:T58	
R6	Experiences Arg1:T47 Arg2:T1	
R7	Experiences Arg1:T47 Arg2:T2	
R8	Experiences Arg1:T47 Arg2:T3	
R9	Location_of Arg1:T39 Arg2:T48	
R10	Causes Arg1:T45 Arg2:T6	
R11	Causes Arg1:T45 Arg2:T44	
R12	Causes Arg1:T45 Arg2:T5	
R13	Location_of Arg1:T62 Arg2:T45	
R14	Location_of Arg1:T61 Arg2:T45	
R15	Location_of Arg1:T49 Arg2:T45	
R16	Causes Arg1:T45 Arg2:T7	
R17	Causes Arg1:T3 Arg2:T2	
R18	Causes Arg1:T45 Arg2:T8	
R19	Causes Arg1:T45 Arg2:T46	
R20	Causes Arg1:T45 Arg2:T9	
R21	Causes Arg1:T45 Arg2:T10	
R22	Overlap Arg1:T6 Arg2:T48	
R23	Overlap Arg1:T44 Arg2:T48	
R24	Overlap Arg1:T5 Arg2:T48	
R25	Experiences Arg1:T51 Arg2:T16	
R26	Experiences Arg1:T51 Arg2:T12	
R27	Causes Arg1:T16 Arg2:T12	
T63	Quantifier_or_Qualifier 574 586	al menos, un
R28	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T63	
T64	Result_or_Value 591 604	mayor de 2 cm
R29	Has_Result_or_Value Arg1:T12 Arg2:T64	
R30	Experiences Arg1:T51 Arg2:T18	
R31	Experiences Arg1:T51 Arg2:T19	
R34	Has_Duration_or_Interval Arg1:T40 Arg2:T52	
R35	Used_for Arg1:T40 Arg2:T20	
R37	Has_Frequency Arg1:T21 Arg2:T53	
R38	Location_of Arg1:T23 Arg2:T22	
R39	Has_Frequency Arg1:T22 Arg2:T53	
T65	CONC 889 898	inclusión
#57	AnnotatorNotes T65	C1512693; Inclusion; Qualitative Concept
R42	Overlap Arg1:T25 Arg2:T54	
R43	Before Arg1:T65 Arg2:T25	
T66	Observation 931 961	disminución del tamaño del AML
R44	Experiences Arg1:T55 Arg2:T66	
R45	Overlap Arg1:T66 Arg2:T54	
R47	Before Arg1:T41 Arg2:T66	
R48	Experiences Arg1:T55 Arg2:T41	
R49	Location_of Arg1:T42 Arg2:T28	
R50	Used_for Arg1:T36 Arg2:T37	
R51	Experiences Arg1:T59 Arg2:T24	
R52	Has_Duration_or_Interval Arg1:T24 Arg2:T60	
T67	Observation 1652 1668	reducción de AML
R53	Experiences Arg1:T59 Arg2:T67	
R54	Causes Arg1:T24 Arg2:T67	
R55	Overlap Arg1:T67 Arg2:T60	
R56	Before Arg1:T38 Arg2:T67	
R57	Experiences Arg1:T59 Arg2:T38	
R33	Before Arg1:T18 Arg2:T17	
R58	Before Arg1:T19 Arg2:T17	
#58	AnnotatorNotes T57	C1546936; Unexpected beneficial effect; Idea or Concept (?)
A3	Experiencer T47 Patient
A4	Experiencer T51 Patient
A5	Experiencer T59 Patient
A6	Experiencer T55 Patient
